IL-23 inhibitors and IBD

IL-23 inhibitors represent a significant advancement in the treatment landscape for inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC). These biologic agents target the interleukin-23 (IL-23) cytokine, specifically its p19 subunit, which plays a crucial role in driving the chronic inflammation underlying IBD. By selectively inhibiting IL-23, these therapies aim to reduce inflammation, promote mucosal healing, and improve patient outcomes.

### **Role of IL-23 in IBD Pathogenesis**

IL-23 is a pro-inflammatory cytokine that is part of the IL-12 family. It is composed of two subunits: p19 (unique to IL-23) and p40 (shared with IL-12). IL-23 is produced by antigen-presenting cells such as dendritic cells and macrophages and plays a central role in the differentiation and maintenance of Th17 cells, a subset of CD4+ T cells. Th17 cells, in turn, produce inflammatory cytokines like IL-17, IL-22, and TNF-α, which contribute to the inflammation and tissue damage seen in IBD. By targeting the p19 subunit, IL-23 inhibitors selectively block IL-23 signaling without affecting IL-12, thereby preserving the protective immune functions of IL-12.

### **Approved IL-23 Inhibitors for IBD**

Several IL-23 inhibitors have demonstrated efficacy and safety in clinical trials and are either approved or under investigation for the treatment of IBD:

1. **Risankizumab**:

• Approved for moderate-to-severe Crohn’s disease.
• Clinical trials (e.g., ADVANCE and MOTIVATE) have shown significant improvements in clinical remission, endoscopic response, and quality of life in patients with CD.
• Demonstrated a favorable safety profile with low rates of infections and adverse events.

2. **Mirikizumab**:

• Recently approved for moderate-to-severe ulcerative colitis.
• Clinical trials (e.g., LUCENT-1 and LUCENT-2) showed significant efficacy in inducing and maintaining clinical remission, endoscopic improvement, and histologic remission in UC patients.
• Safety data suggest a low risk of serious infections and adverse events.

3. **Guselkumab**:

• Currently approved for psoriasis and psoriatic arthritis, with ongoing trials for Crohn’s disease (e.g., GALAXI-1).
• Preliminary data suggest promising efficacy and safety in CD.

4. **Tildrakizumab**:

• Primarily approved for psoriasis but being investigated for IBD.
• Early-phase trials are ongoing to evaluate its effectiveness in CD and UC.

### **Efficacy of IL-23 Inhibitors**

Clinical trials and real-world studies have demonstrated the efficacy of IL-23 inhibitors in both induction and maintenance phases of treatment:

• **Induction Phase**: IL-23 inhibitors have shown rapid reductions in disease activity, with many patients achieving clinical remission and endoscopic improvement within 8-12 weeks.
• **Maintenance Phase**: These agents have demonstrated sustained efficacy over long-term treatment, with many patients maintaining remission and mucosal healing for up to a year or longer.

### **Safety Profile**

IL-23 inhibitors have a favorable safety profile compared to other biologics. Key findings include:

• Low risk of serious infections.
• Minimal immunosuppression compared to anti-TNF agents.
• Rare adverse events, with most being mild-to-moderate in severity (e.g., upper respiratory tract infections, injection site reactions).

### **Position in Treatment Algorithm**

According to the **American Gastroenterological Association (AGA)** and **European Crohn’s and Colitis Organisation (ECCO)** guidelines, IL-23 inhibitors are increasingly being positioned as a valuable option in the treatment of IBD:

1. **Moderate-to-Severe Crohn’s Disease**:

• IL-23 inhibitors, such as risankizumab, are recommended for patients who have failed conventional therapies (e.g., corticosteroids, immunomodulators) or other biologics (e.g., anti-TNF agents, anti-IL-12/23 agents like ustekinumab).
• They are also considered for biologic-naïve patients due to their targeted mechanism of action and favorable safety profile.

2. **Moderate-to-Severe Ulcerative Colitis**:

• Mirikizumab is recommended for patients with inadequate response or intolerance to conventional or biologic therapies.
• Emerging data suggest that IL-23 inhibitors may be particularly effective in patients with a higher inflammatory burden, as evidenced by elevated biomarkers like CRP and fecal calprotectin.

3. **Combination Therapy**:

• Preliminary evidence suggests that IL-23 inhibitors may be used in combination with other biologics (e.g., anti-TNF agents) or small-molecule drugs (e.g., JAK inhibitors like tofacitinib or upadacitinib) to achieve deeper remission in refractory cases.
• However, more research is needed to establish the safety and efficacy of combination regimens.

### **Advantages Over Other Biologics**

IL-23 inhibitors offer several advantages over existing biologics:

• **Selective Targeting**: By targeting the IL-23p19 subunit, these agents avoid inhibiting IL-12, which plays a protective role in immune defense against infections and malignancies.
• **Durable Remission**: IL-23 inhibitors have demonstrated sustained efficacy in maintaining remission and mucosal healing, even in patients who have failed other biologics.
• **Convenient Dosing**: Most IL-23 inhibitors are administered subcutaneously every 4-8 weeks, offering convenience and improved patient adherence.

### **Challenges and Future Directions**

Despite their promise, IL-23 inhibitors face several challenges:

• **Cost**: Like other biologics, IL-23 inhibitors are expensive, which may limit access for some patients.
• **Long-Term Safety**: While short-term safety data are reassuring, long-term safety, particularly regarding the risk of infections or malignancies, needs further evaluation.
• **Biomarker Development**: Identifying biomarkers to predict response to IL-23 inhibitors remains an area of active research, with the goal of personalizing treatment for individual patients.

### **Conclusion**

IL-23 inhibitors represent a major advancement in the management of IBD, addressing unmet needs for patients with moderate-to-severe disease who do not respond adequately to existing therapies. With their targeted mechanism of action, robust efficacy, and favorable safety profile, these agents are poised to play a central role in personalized treatment strategies for Crohn’s disease and ulcerative colitis. Ongoing research, including head-to-head trials and studies exploring combination therapies, will further clarify their place in the therapeutic landscape and expand the possibilities for improving patient outcomes.